| Autor: |
Farzana Islam, Ayan Das, Triparna Majumdar, Arvind Kumar Singh, M Shwethashree, Manickam Ponnaiah, KV Leela, Satyendra Khichar, S Aswathy, R. Sabarinathan, Ashish Surana, Binod Kumar Patro, Yogesh Bahurupi, Sanjay K Rai, Deepak Kumar, C. Palanivel, Anjan Trikha, Baijayantimala Mishra, TS Dipu, Pragati Rathod, Manoj Kumar Gupta, Kiran G. Kulirankal, Vartika Saxena, Ramniwas Jalandra, Sarika P Kombade, Prakash Patel, AV Gayathri, Nishant Kumar Chauhan, Shashi Kant, Tarun Bhatnagar, Sangita Bhalavi, Mannu Jain, Prasanta Raghab Mohapatra, Priya Abraham, Santhosh Kumar Muthusamy, Pankaj Bhardwaj, Vineet Jain, Dinesh Babu, Ashwini Agarwal, Naveet Wig, Puneet Misra, R Deepashree, Smita Sinha, Rima R Sahay, Pragya D Yadav, Amoghashree, Manoj V Murhekar, Dimpal A Nyayanit, Priyanka Pandit Biswas, Lalit Dar, M R Narayana Murthy, Rajendra Joshi, Meenakshi Khapre, Sitanshu Sekhar Kar, Sanjeev Misra, Basavana Gowdappa, Mahendra Kumar Garg, Rahul Dhodapkar, KB Chetak, Minakshi Dhar, M Logaraj, Sarita Wadhava, Abhinendra Kumar, Manish Patel, Deepak Shukla, Naimesh Shah, Ravisekhar Gadepalli, Priyamadhaba Behera, Faheem Ahmed, Jaykaran Charan, Mahalingam Venkateshan, Deepjyoti Kalita, M. Lanord Stanley Jawahar, Mridu Dudeja, Nivedita Gupta, P Ashok, Randeep Guleria, Akhil Dhanesh Goel, Yasir Alvi, Anita M. Shete, Uday Wasudeorao Narlawar, G Vijaykrishnan, Savita Patil, A Tejashree, Manisha Dudhmal, Sunil Kohli, Monika Pathania, Anil Kumar, Anil S. Bilimale, Jeromie Wesley Vivian Thangaraj, Sirshendu Chaudhuri |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
SSRN Electronic Journal. |
| ISSN: |
1556-5068 |
| DOI: |
10.2139/ssrn.3955739 |
| Popis: |
Background: India introduced BBV152/Covaxin and AZD1222/Covishield vaccines from January 2021. We estimated effectiveness of these vaccines against severe Coronavirus disease 2019 (COVID-19) among individuals aged >=45 years. Methods: We did a multi-centric, hospital-based, case–control study between May and July 2021. Cases were severe COVID-19 patients and controls were COVID-19 negative individuals from 11 hospitals. Vaccine effectiveness (VE) was estimated for full (2 doses ≥14days) and partial (1 dose ≥21 days) vaccination; duration between two vaccine doses and against the Delta variant. We used a random effects logistic regression model to calculate adjusted odds ratios (aOR) with 95% CI after adjusting for relevant known confounders. Findings: We enrolled 1,143 cases and 2,541 controls. The VE of full vaccination was 80% (95% CI: 73%-86%) with AZD1222/Covishield and 69% (95% CI: 54%-79%) with BBV152/Covaxin. The VE was highest for a gap of 6-8 weeks between two doses of AZD1222/Covishield (92%, 95% CI: 82%-96%) and BBV152/Covaxin (92%, 95% CI: 26%-99%). The VE estimates were similar against the Delta strain and sub-lineages. Interpretation: BBV152/Covaxin and AZD1222/Covishield were effective against severe COVID-19 among the Indian population during the period of dominance of highly transmissible Delta variant in second wave of pandemic. An escalation of two-dose coverage with COVID-19 vaccines is critical to control the pandemic in the country. Funding Information: Indian Council of Medical Research Declaration of Interests: None to declare. Ethics Approval Statement: We obtained written informed consent from all the participants or their legally authorized representatives. Study procedures were approved by the Institutional Human Ethics Committees of all participating institutions. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
